Prentice Wealth Management LLC Savara Inc Transaction History

Prentice Wealth Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 28, 2022	SELL	$1.1 - $1.58 $1,100 - $1,580	-1,000 Closed	0 $0
Q1 2021 Jun 17, 2021	SELL	$1.17 - $2.33 $1,263 - $2,516	-1,080 Reduced 51.92%	1,000 $2,000
Q1 2021 Jun 08, 2021	BUY	$1.17 - $2.33 $2,433 - $4,846	2,080 New	2,080 $2,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $369M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Prentice Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on Prentice Wealth Management LLC with notifications on news.